Keywords: Gout drug prescribing, Allopurinol, Uloric, Takeda, Krystexxa, Savient, Decision Resources

Allopurinol remains gout market leader but Uloric making inroads, study finds

Article | 18 April 2012

Print This

Most surveyed rheumatologists, nephrologists and primary care physicians cite increased use of Takeda’s Uloric (febuxostat), in the last ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in